![Benjamin Maynor](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Benjamin Maynor
Corporate Officer/Principal bei
American Chemical Society
Profil
Benjamin Maynor is a member of the American Chemical Society and the American Association of Pharmaceutical Scientists.
He was previously the Senior Vice President-Research & Development at Liquidia Technologies, Inc. from 2015 to 2020, an Associate at The University of North Carolina at Chapel Hill in 2004-2005, a Scientist at Polestar Technologies, Inc. from 1996 to 1999, and the Vice President-Research at Envisia Therapeutics, Inc. from 2013 to 2015.
He holds a doctorate from Duke University and an undergraduate degree from Harvard University.
Currently, Dr. Maynor holds positions at the American Chemical Society and the American Association of Pharmaceutical Scientists.
Aktive Positionen von Benjamin Maynor
| Unternehmen | Position | Beginn |
|---|---|---|
American Chemical Society
 American Chemical Society Miscellaneous Commercial ServicesCommercial Services Operates as scientific society that supports scientific inquiry in the field of chemistry | Corporate Officer/Principal | - |
American Association of Pharmaceutical Scientists
 American Association of Pharmaceutical Scientists BiotechnologyHealth Technology Engages in research and development of pharmaceutical products | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Benjamin Maynor
| Unternehmen | Position | Ende |
|---|---|---|
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops particle-based vaccines and therapeutics for prevention and treatment of human disease | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2020 |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Corporate Officer/Principal | 01.03.2015 |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.09.2005 |
Polestar Technologies, Inc.
 Polestar Technologies, Inc. Industrial MachineryProducer Manufacturing Provides optical monitoring, sensing, and probes | Corporate Officer/Principal | 01.06.1999 |
Ausbildung von Benjamin Maynor
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
89
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops particle-based vaccines and therapeutics for prevention and treatment of human disease | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Chemical Society
American Chemical Society Miscellaneous Commercial ServicesCommercial Services Operates as scientific society that supports scientific inquiry in the field of chemistry | Commercial Services |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Association of Pharmaceutical Scientists
American Association of Pharmaceutical Scientists BiotechnologyHealth Technology Engages in research and development of pharmaceutical products | Health Technology |
Polestar Technologies, Inc.
Polestar Technologies, Inc. Industrial MachineryProducer Manufacturing Provides optical monitoring, sensing, and probes | Producer Manufacturing |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
Wählen Sie MarketScreener 
